Johnson & Johnson has delivered a strong 28% total return year-to-date in 2026, outperforming major benchmarks like the S&P 500 ETF and healthcare sector ETF XLV. Despite solid second-quarter results and an upgraded full-year 2026 guidance driven by pharmaceutical momentum, the stock now trades at a premium valuation. Key risks include potential softness in MedTech growth, ongoing litigation challenges, and broader macroeconomic uncertainties. Technically, the stock remains in an uptrend but shows signs of possible near-term consolidation due to negative RSI divergence and high valuation, leading analysts to maintain a hold rating rather than recommending a buy or sell.
In 2026, among defensive stocks, Johnson & Johnson outperformed with a 35% gain driven by strong oncology and immunology sales and a robust pipeline. Coca-Cola followed with a 28% rise, benefiting from steady global volume and pricing power, while Pr...
Johnson & Johnson has increased its dividend for the 64th consecutive year, paying $1.34 per share quarterly, reflecting a 3.1% raise. The company maintains a strong financial position with a payout ratio near 48%, supported by robust operating cash ...
